Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03912402
Other study ID # BCD-100-4/CAESURA
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 25, 2018
Est. completion date July 7, 2020

Study information

Verified date May 2019
Source Biocad
Contact Mariia S Shustova, MD
Phone +7-(812)-380-49-33
Email biocad@biocad.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and bevacizumab as first-line treatment in patients with recurrent/persistent or metastatic cervical cancer.


Description:

The study will be conducted in two stages. At the first stage patients will receive up to 6 cycles of BCD-100 in combination with platinum-based chemotherapy and bevacizumab or until unacceptable toxicity or disease progression. Patients who have demonstrated a positive antitumor effect (stabilization of the disease, partial or complete response) and who have no signs of unacceptable toxicity could continue to receive up to 12 cycles of maintenance therapy of BCD-100 in combination with bevacizumab or until unacceptable toxicity or disease progression.


Recruitment information / eligibility

Status Recruiting
Enrollment 49
Est. completion date July 7, 2020
Est. primary completion date July 7, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Signed Informed Consent Form and the subject's ability to follow the Protocol requirements;

2. Age: 18 years and older at the signing of the informed consent;

3. Histologically verified (documented) adenomatous, adenosquamous, or squamous cervical cancer;

4. Newly diagnosed metastatic cervical cancer or recurrent/persistent cervical cancer;

5. Availability of archival histological tumor material (paraffin blocks) or consent to biopsy;

6. ECOG performance status of 0 or 1;

7. At least one RESICT 1.1-defined measurable target lesion confirmed by an independent review;

8. Patients with reproductive potential must agree to practice acceptable methods of birth control throughout the entire trial period, starting from signing the informed consent and up to 24 weeks after the last dose of investigational product.

Exclusion Criteria:

1. Indications for radical therapy (surgical or radiotherapy);

2. Prior systemic treatment for recurrent, secondarily progressive or initially metastatic disease;

3. Chemotherapy, and / or radiation therapy, and / or chemo-radiation therapy for early stages of cervical cancer with disease progression / recurrence earlier than 6 months after the end of therapy;

4. Patients with severe concomitant factors or the effects of their treatment (hemorrhage, perforation, fistula);

5. Central nervous system (CNS) metastases;

6. Concomitant diseases or conditions which pose a risk of AE development during study treatment:

1. uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg;

2. stable angina functional class III-IV;

3. unstable angina or myocardial infarction less than 6 months prior to randomization;

4. NYHA Grade III-IV congestive heart failure;

5. atopic asthma, Stage III-IV COPD, angioedema;

6. severe respiratory failure;

7. any other diseases which pose unacceptable risk of AE development during study treatment in Investigator's opinion;

7. Active or known or suspected autoimmune disease (subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll);

8. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to randomization;

9. Established diagnosis of coagulopathy and / or clinically significant bleeding, including nasal bleeding;

10. The need for regular intake of anticoagulants, antiplatelet agents, platelet function inhibitors, or their course application less than 1 month before being included in the study;

11. Hematologic disorders: neutrophils <1500/mcl or platelets <100 000/mcl or hemoglobin <90 g/l;

12. Renal disorders: creatinine = 1.5 x UNL;

13. Hepatic disorders: bilirubin = 1.5 x UNL (excluding Gilbert's syndrome if bilirubin < 50 µmol/l) or AST/ALT = 3 x UNL (excluding subjects with liver metastases if AST/ALT < 5 x UNL) or alkaline phosphatase = 5 x UNL;

14. Any anti-cancer therapy less than 28 days prior to randomization;

15. Previous use of PD-1/PD-L1/PD-L2/CTLA-4 agent;

16. Previous use of VEGF/VEGFR inhibitors, including bevacizumab, ramucirumab, aflibercept and tyrosine kinase inhibitors;

17. Concomitant cancer (except for cervical carcinoma in situ after radical surgery or basal cell/ squamous cell carcinoma after radical surgery);

18. Clinically significant (=2 degree) peripheral neuropathy or hearing impairment;

19. Any condition that prevents a patient from following the Protocol procedures (dementia, neurological or mental disorders, drug/alcohol abuse, etc.);

20. Simultaneous participation in other clinical trials , participation in other clinical trials within 30 days prior to the first dose of the investigational product;

21. Acute infection or the acute phase of chronic infection within 28 days prior the first dose of the investigational product;

22. Active HBV/HCV/HIV infection, active syphilis;

23. Patients unable to receive an IV infusions;

24. Patients unable to receive an IV contrast agent;

25. Hypersensitivity to any of the components of BCD-100, bevacizumab, paclitaxel, cisplatin (or carboplatin);

26. Life expectancy less than 6 months;

27. Significant adverse events (AE) of previous therapy excluding chronic and/or irreversible events which cannot affect study drug safety evaluation (e.g. alopecia);

28. Pregnancy or breast-feeding.

Study Design


Intervention

Biological:
BCD-100
Anti-PD-1 monoclonal antibody, IV infusion
Bevacizumab
IV infusion
Drug:
Paclitaxel
IV infusion
Cisplatin (or carboplatin)
IV infusion

Locations

Country Name City State
Russian Federation Arkhangelsk Clinical Oncology Dispensary Arkhangel'sk Arkhangelsk Oblast
Russian Federation City Hospital No. 5 Barnaul Altai Krai
Russian Federation Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine Chelyabinsk Chelyabinsk Oblast
Russian Federation Sverdlovsk Regional Oncology Center Ekaterinburg Sverdlovsk Oblast
Russian Federation Republican Clinical Oncology Cente Kazan Republic Of Tatarstan
Russian Federation Clinical Oncologic Dispensary No. 1 Krasnodar Krasnodar Kari
Russian Federation Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky Krasnoyarsk Krasnoyarsk Krai
Russian Federation JSC "Medsi Group of Companies" Moscow
Russian Federation Moscow City Oncology Hospital No. 62 Moscow
Russian Federation Moscow Clinical Scientific and Practical Center named A.S. Loginova Moscow
Russian Federation N.N. Blokhin National Medical Research Center of Oncology Moscow
Russian Federation N.N. Blokhin National Medical Research Center of Oncology (2) Moscow
Russian Federation Murmansk Regional Clinical Hospital named after P.A. Bayandina Murmansk Murmansk Oblast
Russian Federation National Medical Radiology Research Center Obninsk Kaluga Oblast
Russian Federation Clinical Oncology Dispensary Omsk Omsk Oblast
Russian Federation LLC "New Clinic" Pyatigorsk Stavropol Krai
Russian Federation JSC "Modern Medical Technologies" Saint Petersburg
Russian Federation LLC "AB Medical Group" Saint Petersburg
Russian Federation N.N. Petrov National Medical Research Center of Oncology Saint Petersburg
Russian Federation N.N. Petrov National Medical Research Center of Oncology (2) Saint Petersburg Saint-Petersburg
Russian Federation Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) Saint Petersburg
Russian Federation Republican Oncology Center Saransk Republic Of Mordovia
Russian Federation Stavropol Regional Clinical Oncology Center Stavropol' Stavropol Krai
Russian Federation Regional Clinical Oncology Hospital Yaroslavl Yaroslavskaya Oblast

Sponsors (1)

Lead Sponsor Collaborator
Biocad

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) ORR is defined as the percentage of the participants in the mITT population who have a Complete Response or a Partial Response. The ORR will be assessed by a blind independent central reviewer per RECIST 1.1 and iRECIST. 6 months
Secondary Median Progression-free Survival (PFS) 1 year
Secondary 1-year Progression-free Survival (PFS) 1 year
Secondary 1-year Overall Survival (OS) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A